Allakos — Corporate Update (January 2024)
35 slides from Allakos's corporate update, Jan 17, 2024
Slide 1: Corporate Update January 2024
Corporate Update January 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); estimated lirentelimab closeout,
Slide 3: Agenda
Agenda Robert Alexander, CEO Introduction Craig Paterson, CMO Results of ATLAS and MAVERICK Phase 2 Studies Baird Radford, CFO Restructuring and Financial Implications Robert Alexander, CEO AK006 Program Update Q&A
Slide 4: ATLAS: Phase 2 Study of Lirentelimab in Atopic Dermatitis
ATLAS: Phase 2 Study of Lirentelimab in Atopic Dermatitis
Slide 5: Phase 2 Atopic Dermatitis Study Design
Phase 2 Atopic Dermatitis Study Design Multi-center, randomized, DB, placebo-controlled Chronic disease that has been present ≥3 years EASI score ≥16 Involvement of ≥10% of body surface area IGA score ≥3 Inadequate control by topical treatments Includes patients with prior biologics treatment 131 ad
Slide 6: ATLAS: Baseline Demographics & Patient Characteristics
ATLAS: Baseline Demographics & Patient Characteristics Baseline Characteristics (mITT population) Phase 2 ATLAS (AD) Patient Characteristics Lirentelimab n=61 Placebo n=61 All n=122 Age (years), median (IQR) 39 (31-54) 35 (26-49) 37 (26-53) Female sex, n (%) 32 (52.5%) 34 (55.7%) 66 (54.1%) White, n
Slide 7: ATLAS Primary Efficacy Endpoint
ATLAS Primary Efficacy Endpoint Proportion of EASI-75 Responders at Week 14 (mITT) % of Subjects (11/61) (14/61) Lirentelimab Placebo *ns
Slide 8: Secondary Endpoint: Change in EASI Score
Secondary Endpoint: Change in EASI Score Change in EASI Score from Baseline to Week 14 (mITT) Percent Change EASI LS Mean Change from BL Absolute Change Lirentelimab (n=61) Placebo (n= 61) 26.9 26.8 Median BL = Lirentelimab (n=61) Placebo (n= 61) EASI LS Mean % Change from BL *ns *ns
Slide 9: Significant Change in EASI Scores in Patients with Higher Inflammatory Disease Burden
Significant Change in EASI Scores in Patients with Higher Inflammatory Disease Burden Percent Change in EASI Score from Baseline to Week 14 (mITT) Baseline IGA-4 Difference from placebo p-values derived using MMRM Baseline IGA-3 Lirentelimab (n=29) Placebo (n= 30) 24.0 Median BL = Lirentelimab (n=32
Slide 10: Exploratory Endpoint: Improvement in ppNRS (Itch)
Exploratory Endpoint: Improvement in ppNRS (Itch) Proportion of ppNRS Responders at Week 14 (mITT) Difference from placebo p-values derived using Cochran-Mantel-Haenszel (CMH) Includes all subjects regardless of baseline ppNRS. No minimum ppNRS required for study entry. % of Subjects (14/61) (7/61)
Slide 11: MAVERICK: Phase 2b Study of Lirentelimab in Chronic Spontaneous Urticaria
MAVERICK: Phase 2b Study of Lirentelimab in Chronic Spontaneous Urticaria
Slide 12: Phase 2b Chronic Spontaneous Urticaria Study
Phase 2b Chronic Spontaneous Urticaria Study Multi-center, randomized, DB, placebo-controlled Active moderate-to-severe symptoms CSU diagnosis with onset ≥6 months prior to screening Diagnosis of CSU refractory to antihistamines Presence of itch and hives despite current use of antihistamines UAS7 s
Slide 13: MAVERICK: Baseline Demographics & Patient Characteristics
MAVERICK: Baseline Demographics & Patient Characteristics Baseline Characteristics (mITT population) Phase 2 MAVERICK (CSU) Patient Characteristics Lirentelimab n=64 Placebo n=59 All n=123 Age, mean ± SD 42 ± 14 46 ± 16 44 ± 15 Female sex, n (%) 48 (75.0%) 55 (93.2%) 103 (83.7%) White, n (%) 52 (81.
Slide 14: MAVERICK Primary Efficacy Endpoint
MAVERICK Primary Efficacy Endpoint Change in UAS7 from Baseline to Week 12 (mITT) Percent Change Absolute Change 32.4 UAS7 LS Mean % Change from BL UAS7 LS Mean Change from BL Lirentelimab (n=64) Placebo (n=59) Lirentelimab (n=64) Placebo (n=59) 31.4 BL = *ns *ns
Slide 15: UAS7 Response vs. Placebo
UAS7 Response vs. Placebo Proportion of Subjects Achieving UAS7 ≤6 and UAS7 =0 at Week 12 (mITT) Lirentelimab (n=64) Placebo (n=59) % of Subjects (9/64) (7/59) (0/59) UAS7 ≤6 UAS7 =0 *ns (4/64) *ns
Slide 16: Complete Response in Hives and Itch
Complete Response in Hives and Itch % of Subjects (2/59) (4/64) Lirentelimab Placebo Lirentelimab (1/59) (6/64) Placebo % of Subjects *ns *ns Proportion of Complete Responders in Hives and Itch at Week 12 (mITT) Achieving HSS7=0 Achieving ISS7=0
Slide 17: Robust Depletion of Blood Eosinophils with SC Lirentelimab
Robust Depletion of Blood Eosinophils with SC Lirentelimab Blood Eosinophils over Time (mITT) Study Weeks Dose Median Blood Eos (cells/µL) BL ATLAS Lirentelimab (n=61) ATLAS PBO (n=61) Dose Median Blood Eos (cells/µL) BL Study Weeks ATLAS (AD) MAVERICK (CSU) MAVERICK Lirentelimab (n=64) MAVERICK PBO
Slide 18: Allako of
Allako of
Slide 19: Overall Safety Summary
Overall Safety Summary Safety profile of SC lirentelimab was consistent with previously reported lirentelimab studies Most common adverse events were injection-related reactions (IRRs) ATLAS (AD): 18.5% lirentelimab experienced IRRs vs. 6.2% placebo MAVERICK (CSU): 18.2% lirentelimab experienced IRR
Slide 20: Financial Update
Financial Update Alakos%g
Slide 21: Expected Cash Runway into Middle of 2026
Expected Cash Runway into Middle of 2026 Estimated 2024 Net Cash Used in Operating Activities Estimated net cash used in operating activities (GAAP) $85 to $90 million Less: estimated lirentelimab closeout, severance and other costs ($30 million) Adjusted net cash used in operating activities (non-G
Slide 22: AK006 Development Plans and Update
AK006 Development Plans and Update
Slide 23: Siglec-6 Biology and AK006
Siglec-6 is a more potent inhibitory receptor than Siglec-8 Siglec-6 regulates more cellular processes than Siglec-8: Signal Transduction Transcription Translation Cellular metabolism Degranulation AK006 has two key attributes Long residence time on the cell surface which correlates to increased inh
Slide 24: Siglec-6 and Siglec-8 Differentially Interact with Proteins that Regulate Mast Cell Activity
Siglec-6 and Siglec-8 Differentially Interact with Proteins that Regulate Mast Cell Activity Gray lines represent direct interaction Cytokine Signaling Protein Processing (Translation) TGFb Signaling Interferon-Related Cytoplasmic Transport Mitochondrial Translocation Ubiquitin Activity (Protein Deg
Slide 25: AK006 was Designed to Drive Maximal Mast Cell Inhibition
AK006 was Designed to Drive Maximal Mast Cell Inhibition AK002 AK006 Mast cell inhibition for AK002 and AK006 requires Fc-Fc𝛾 receptor interaction Binding of AK002 induces Siglec-8 internalization, limiting mast cell inhibition AK006 displays a high residence time on mast cells which is associated…
Slide 26: AK006 Displays Significantly Stronger MC Inhibition than AK002 in Preclinical Studies
AK006 Displays Significantly Stronger MC Inhibition than AK002 in Preclinical Studies IgE Activation AK006 inhibits IgE-dependent and –independent modes of MC activation better than AK002 n=3 human donors SOURCE: Korver, W. et al Allergy 2024. KIT Activation Peritoneal Mast Cells MRGPRX2 Activation
Slide 27: AK006 Reduces Human Mast Cells via Antibody-Dependent Cellular Phagocytosis
AK006 Reduces Human Mast Cells via Antibody-Dependent Cellular Phagocytosis in Preclinical Studies AK006 can reduce mast cell numbers and mediate broad inhibition Ex Vivo Human Tissue Mast Cells - IFN𝞬 Activated Macrophages + IFN𝞬 Activated Macrophages Mast Cells in Tissue * p < 0.01; n=3 human…
Slide 28: AK006 Inhibits Mast Cell Activation in Human Tissues
AK006 Inhibits Mast Cell Activation in Human Tissues IgE-Activated Human Tissue Mast Cells AK006 inhibits IgE-mediated mast cell activation Human Mast Cell Activation Assay n=3 human donors SOURCE: Schanin J, et al. EAACI 2022 Presentation.
Slide 29: AK006 Protects Against Systemic Anaphylaxis in Humanized Mice
AK006 Protects Against Systemic Anaphylaxis in Humanized Mice Humanized Model of Anaphylactic Death Systemic Anaphylaxis AK006 inhibits IgE-mediated mast cell activation in vivo Humanized Mouse Model of Anaphylaxis Anaphylactic Death SOURCE: Schanin, J et al. Communications Biology 2022
Slide 30: AK006 Reduces Allergic Enteritis in Siglec-6 Transgenic Mice
AK006 Reduces Allergic Enteritis in Siglec-6 Transgenic Mice AK006 reduces allergen-mediated GI inflammation via mast cell inhibition in vivo SOURCE: Allakos Data on File. Stomach Mast Cells p < 0.05, n=6 mice/group Transcriptional Profiling of Stomach Mast Cells Corporate
Slide 31: AK006 Phase 1 Study Design
AK006 Phase 1 Study Design Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts in Healthy Volunteers Randomized, double-blind, placebo-controlled Intravenous AK006 SAD: 5, 20, 80, 240, 720 mg MAD: 80, 240, 720 mg monthly Subcutaneous AK006 150 and 720 mg Planned CSU Cohort Randomiz
Slide 32: AK006 Clinical Development Plan
AK006 Clinical Development Plan LOW/MOD 2023 2024 2025 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Part C: CSU Patients Data Availability (n=30) Part B: MAD in HVs (3 Cohorts) Part A: SAD in HVs (5 Cohorts) Ph1 First-in-Human Study Today Bioavailability Ph1b Study in TBD Indication Part D: SC in HVs (2 Cohorts) C
Slide 33: Upcoming AK006 Milestones
Upcoming AK006 Milestones Q1 2024: Complete SAD and MAD dosing with Intravenous (IV) AK006 in healthy volunteers. Q1 2024: Initiate the randomized, double-blind, placebo-controlled subcutaneous (SC) AK006 cohort in healthy volunteers. Q2 2024: Report SAD and MAD safety, pharmacokinetics (PK), and ph
Slide 34: Allako of
Allako of
Slide 35: Thank You
Thank You